Correlation Between the CYP2C19 Phenotype Status and the Results of Three Different Platelet Function Tests in Cardiovascular Disease Patients Receiving Antiplatelet Therapy: An Emphasis on Newly Introduced Platelet Function Analyzer-200 P2Y Test
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: An association has been reported between CYP2C19 polymorphism and the altered antiplatelet activity of clopidogrel. We investigated this association using the newly introduced platelet function analyzer (PFA)-200 (INNOVANCE PFA-200 System; Siemens Healthcare, Germany) P2Y test. Methods: Polymorphisms of CYP2C19*2, *3, *17 and the degree of inhibition of platelet function were determined in 83 patients. Three different platelet function tests were used to evaluate the degree of platelet inhibition and to check the association with genotype. Results: The post-procedure PFA-200 values of extensive metabolizers (EM) patients (285.3±38.8) were higher than those of intermediate metabolizers (IM) and poor metabolizers (PM) patients (227.7±98.3 and 133.7±99.2, respectively; P=0.024). Light transmittance aggregometry (LTA) and the VerifyNow system showed that the post-procedure values for EM patients were lower than those of IM and PM patients (LTA: 24.4±15.7, 34.1±17.6, and 42.2±16.9, respectively, P<0.001; VerifyNow: 133.2±60.5, 171.5±42.6, and 218.7±59.3, respectively, P<0.001). The high residual platelet reactivity (HPR) rates were significantly different among the EM, IM, and PM groups using PFA-200 (PM:IM:EM=82.4:40.6:11.8, P<0.001). Conclusions: Approximately, 59.0% of Korean patients with cardiovascular disease receiving clopidogrel had CYP2C19 loss-of-function genotypes classified as IM or PM, and the frequency was similar to the data from Asian people. The PFA-200, LTA, and VerifyNow platelet function tests revealed evidence of a significant association between the efficacy of clopidogrel and CYP2C19 genotypes.
Abstract
Background: An association has been reported between CYP2C19 polymorphism and the altered antiplatelet activity of clopidogrel. We investigated this association using the newly introduced platelet function analyzer (PFA)-200 (INNOVANCE PFA-200 System; Siemens Healthcare, Germany) P2Y test. Methods: Polymorphisms of CYP2C19*2, *3, *17 and the degree of inhibition of platelet function were determined in 83 patients. Three different platelet function tests were used to evaluate the degree of platelet inhibition and to check the association with genotype. Results: The post-procedure PFA-200 values of extensive metabolizers (EM) patients (285.3±38.8) were higher than those of intermediate metabolizers (IM) and poor metabolizers (PM) patients (227.7±98.3 and 133.7±99.2, respectively; P=0.024). Light transmittance aggregometry (LTA) and the VerifyNow system showed that the post-procedure values for EM patients were lower than those of IM and PM patients (LTA: 24.4±15.7, 34.1±17.6, and 42.2±16.9, respectively, P<0.001; VerifyNow: 133.2±60.5, 171.5±42.6, and 218.7±59.3, respectively, P<0.001). The high residual platelet reactivity (HPR) rates were significantly different among the EM, IM, and PM groups using PFA-200 (PM:IM:EM=82.4:40.6:11.8, P<0.001). Conclusions: Approximately, 59.0% of Korean patients with cardiovascular disease receiving clopidogrel had CYP2C19 loss-of-function genotypes classified as IM or PM, and the frequency was similar to the data from Asian people. The PFA-200, LTA, and VerifyNow platelet function tests revealed evidence of a significant association between the efficacy of clopidogrel and CYP2C19 genotypes.
참고문헌 (23)
- Gurbel PA, "Platelet function monitoring in patients with coronary artery disease", J Am Coll Cardiol, 51, pp.1404~1411 (2008)
- 박경진, "Clinical, Pharmacokinetic, and Pharmacogenetic Determinants of Clopidogrel Resistance in Korean Patients with Acute Coronary Syndrome", Annals of Laboratory Medicine, 31(2), pp.91~94 (2011), 대한진단검사의학회
- Marcucci R, "Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up", Circulation, 119, pp.237~242 (2009)
- Ferri N, "Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties", Drugs, 73, pp.1681~1709 (2013)
- Jeong YH, "Effect of CYP2C19*2 and *3 loss-of-function alleles on platelet reactivity and adverse clinical events in East Asian acute myocardial infarction survivors treated with clopidogrel and aspirin", Circ Cardiovasc Interv, 4, pp.585~594 (2011)
- Renda G, "Inconsistency of different methods for assessing ex vivo platelet function: relevance for the detection of aspirin resistance", Haematologica, 95, pp.2095~2101 (2010)
- Lordkipanidzé M, "A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease", Eur Heart J, 28, pp.1702~1708 (2007)
- Hu YF, "Differences in high on-treatment platelet reactivity between intra-coronary and peripheral blood after dual anti-platelet agents in patients with coronary artery disease", Thromb Haemost, 110, pp.124~130 (2013)
- Koessler J, "The new INNOVANCE® PFA P2Y cartridge is sensitive to the detection of the P2Y12 receptor inhibition", Platelets, 22, pp.20~27 (2011)
- Choi JL, "Platelet function tests: a review of progresses in clinical application", Biomed Res Int, 2014, pp.456569~ (2014)
- Rosiak M, "Effect of ASA dose doubling versus switching to clopidogrel on plasma inflammatory markers concentration in patients with type 2 diabetes and high platelet reactivity: the AVOCADO study", Cardiol J, 20, pp.545~551 (2013)
- Marcucci R, "High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting", Thromb Haemost, 104, pp.279~286 (2010)
- Tantry US, "Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding", J Am Coll Cardiol, 62, pp.2261~2273 (2013)
- Stimpfle F, "Impact of point-of-care testing for CYP2C19 on platelet inhibition in patients with acute coronary syndrome and early dual antiplatelet therapy in the emergency setting", Thromb Res, 134, pp.105~110 (2014)
- Dawson-Saunders B, "Basic and clinical biostatistics", pp.2004, Lange Medical Books
- Scott SA, "Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update", Clin Pharmacol Ther, 94, pp.317~323 (2013)
- Nakata T, "Relationship between CYP2C19 loss-of-function polymorphism and platelet reactivities with clopidogrel treatment in Japanese patients undergoing coronary stent implantation", Circ J, 77, pp.1436~1444 (2013)
- Mega JL, "Cytochrome p-450 polymorphisms and response to clopidogrel", N Engl J Med, 360, pp.354~362 (2009)
- Zhang HZ, "Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI", Platelets, 25, pp.285~291 (2014)
- Janssen PW, "Platelet function testing and tailored antiplatelet therapy", J Cardiovasc Transl Res, 6, pp.316~328 (2013)
- Wheeler GL, "The Ultegra rapid platelet-function assay: comparison to standard platelet function assays in patients undergoing percutaneous coronary intervention with abciximab therapy", Am Heart J, 143, pp.602~611 (2002)
- van Werkum JW, "A head-to-head comparison between the VerifyNow P2Y12 assay and light transmittance aggregometry for monitoring the individual platelet response to clopidogrel in patients undergoing elective percutaneous coronary intervention", J Thromb Haemost, 4, pp.2516~2518 (2006)
- Breet NJ, "Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation", JAMA, 303, pp.754~762 (2010)